SCHEMBL1369814

SCHEMBL1369814

CCCc1ccncc1Br

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2E1 P05181 4/20 0.47
CYP2C8 P10632 4/20 0.47
CYP2D6 P10635 4/20 0.47
CYP2A6 P11509 4/20 0.47
CYP2B6 P20813 4/20 0.47
CYP2C19 P33261 4/20 0.47
CYP2C9 P11712 3/20 0.47
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
AOC1 P19801 6/20 0.41
AOC3 Q16853 6/20 0.41
PARP1 P09874 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
LOXL2 Q9Y4K0 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.34
AXL P30530 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7253760 0.88 L3MBTL1 (0.42) CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6
SCHEMBL746866 0.86 TDP1 (0.49) CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6
SCHEMBL1371438 0.85 TDP1 (0.47) CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6
SCHEMBL793614 0.83
SCHEMBL31651759 0.83
SCHEMBL10954433 0.80 CYP2E1 (0.51) CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6
SCHEMBL16212886 0.79 PARP1 (0.37) CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6
SCHEMBL30107212 0.79 PARP1 (0.37) CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6
SCHEMBL20519350 0.79 PARP1 (0.35) CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6
SCHEMBL7349582 0.78 PARP1 (0.36) AOC1AOC3PARP1LOXL2AXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210276987-A1 PHARMACEUTICAL AGENTS FOR USE IN SMOKING AND TOBACCO CESSATION WASHINGTON STATE UNIVERSITY (US) 2021-09-09 US disclosed
WO-2021003398-A1 INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2021-01-07 WO disclosed
CN-102438991-B Carbinol compounds having a heterocyclic linker KOWA CO.,LTD. (JP) 2015-08-26 CN disclosed
US-20130045935-A1 FLAVONOID DIMERS AND THEIR USE THE HONG KONG POLYTECHNIC UNIVERSITY (CN) 2013-02-21 US disclosed
US-8273769-B2 Phenoxy acetic acid derivatives MERCK SERONO SA (CH) 2012-09-25 US disclosed
US-8273769-B2 Phenoxy acetic acid derivatives MERCK SERONO SA (CH) 2012-09-25 US disclosed
US-8273769-B2 Phenoxy acetic acid derivatives MERCK SERONO SA (CH) 2012-09-25 US disclosed
EP-2396295-A1 PHENOXY ACETIC ACID DERIVATIVES Merck Serono S.A. (CH) 2011-12-21 EP disclosed
US-20110288066-A1 PHENOXY ACETIC ACID DERIVATIVES MERCK SERONO S.A. (CH) 2011-11-24 US disclosed
US-20110288066-A1 PHENOXY ACETIC ACID DERIVATIVES MERCK SERONO S.A. (CH) 2011-11-24 US disclosed
US-20110288066-A1 PHENOXY ACETIC ACID DERIVATIVES MERCK SERONO S.A. (CH) 2011-11-24 US disclosed
WO-2010092043-A1 PHENOXY ACETIC ACID DERIVATIVES MERCK SERONO S.A. (CH) 2010-08-19 WO disclosed
WO-2010092043-A1 PHENOXY ACETIC ACID DERIVATIVES MERCK SERONO S.A. (CH) 2010-08-19 WO disclosed
WO-2006014762-A1 SUBSTITUTED AMIDE BETA SECRETASE INHIBITORS SCHERING CORPORATION (US) 2006-02-09 WO disclosed
US-20050059726-A1 Pyrrolidine-2-ones as factor xa inhibitors GLAXO GROUP LIMITED (GB) 2005-03-17 US disclosed
EP-1456172-A1 PYRROLIDINE-2-ONES AS FACTOR XA INHIBITORS GLAXO GROUP LIMITED (GB) 2004-09-15 EP disclosed
WO-2003053925-A1 PYRROLIDINE-2-ONES AS FACTOR XA INHIBITORS GLAXO GROUP LIMITED (GB) 2003-07-03 WO disclosed
WO-2003027101-A1 SUBSTITUTED 3-PYRIDYL PYRROLES AND 3-PYRIDYL PYRAZOLES AS C17,20 LYASE INHIBITORS BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-03 WO disclosed
WO-2003027105-A1 SUBSTITUTED 3-PYRIDYL THIOPHENES AS C17,20 LYASE INHIBITORS BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130045935-A1 FLAVONOID DIMERS AND THEIR USE DHFR, CCNY, ETFB CYP2E1 473/4885CYP2C8 272/4885CYP2D6 26/4885
US-20110288066-A1 PHENOXY ACETIC ACID DERIVATIVES HRH2, HRH1, HRH3 CYP2E1 674/4885CYP2C8 2850/4885CYP2D6 1672/4885
US-20050059726-A1 Pyrrolidine-2-ones as factor xa inhibitors TFPI, F2, SERPINC1 CYP2E1 2775/4885CYP2C8 1313/4885CYP2D6 1433/4885
US-20210276987-A1 PHARMACEUTICAL AGENTS FOR USE IN SMOKING AND TOBACCO CESSATION CYP2A6, CYP2B6, CYP2D6 CYP2E1 19/4885CYP2C8 67/4885CYP2D6 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.